<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under
Section 12(g) of the Securities Exchange Act of 1934 or
Suspension of Duty to File Reports under
Sections 13 and 15(d) of the Securities Exchange Act of 1934.
Commission File Number: 0-12081
AQUILA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
175 CROSSING BOULEVARD, FRAMINGHAM, MA 01702
(508) 628-0100
(Address, including zip code, and telephone number,
including area code, of registrant's
principal executive offices)
COMMON STOCK, $.01 PAR VALUE
COMMON STOCK PURCHASE RIGHTS
(Title of each class of securities covered by this Form)
NONE
(Titles of all other classes of securities for
which a duty to file reports under
Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) [X] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 12g-4(a)(2)(ii) [ ] Rule 15d-6 [ ]
Rule 12h-3(b)(1)(i) [X]
Approximate number of holders of record as of the certification or notice
date: 1
Pursuant to the requirements of the Securities Exchange Act of 1934, AQUILA
BIOPHARMACEUTICALS, INC. has caused this certification/notice to be signed on
its behalf by the undersigned duly authorized person.
Date: November 17, 2000 AQUILA BIOPHARMACEUTICALS, INC.
By: /s/ Garo H. Armen, Ph.D.
---------------------------------------
Garo H. Armen, Ph.D.
President
